CA2386000A1 - Treatment of diabetic nephropathy and microalbuminuria - Google Patents

Treatment of diabetic nephropathy and microalbuminuria Download PDF

Info

Publication number
CA2386000A1
CA2386000A1 CA002386000A CA2386000A CA2386000A1 CA 2386000 A1 CA2386000 A1 CA 2386000A1 CA 002386000 A CA002386000 A CA 002386000A CA 2386000 A CA2386000 A CA 2386000A CA 2386000 A1 CA2386000 A1 CA 2386000A1
Authority
CA
Canada
Prior art keywords
individual
salviae miltiorrhizae
diabetic
level
miltiorrhizae radix
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002386000A
Other languages
English (en)
French (fr)
Inventor
Hai-Ri Li
Hyun Chul Lee
Mankil Jung
Sudhir V. Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shiva Biomedical LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2386000A1 publication Critical patent/CA2386000A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA002386000A 1999-09-29 2000-09-21 Treatment of diabetic nephropathy and microalbuminuria Abandoned CA2386000A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/408,436 1999-09-29
US09/408,436 US6149915A (en) 1999-09-29 1999-09-29 Treatment of diabetic nephropathy and microalbuminuria
PCT/US2000/025783 WO2001022981A1 (en) 1999-09-29 2000-09-21 Treatment of diabetic nephropathy and microalbuminuria

Publications (1)

Publication Number Publication Date
CA2386000A1 true CA2386000A1 (en) 2001-04-05

Family

ID=23616291

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002386000A Abandoned CA2386000A1 (en) 1999-09-29 2000-09-21 Treatment of diabetic nephropathy and microalbuminuria

Country Status (7)

Country Link
US (3) US6149915A (cg-RX-API-DMAC7.html)
EP (1) EP1218020A1 (cg-RX-API-DMAC7.html)
JP (1) JP2003510286A (cg-RX-API-DMAC7.html)
CN (1) CN1387439A (cg-RX-API-DMAC7.html)
AU (1) AU771275B2 (cg-RX-API-DMAC7.html)
CA (1) CA2386000A1 (cg-RX-API-DMAC7.html)
WO (1) WO2001022981A1 (cg-RX-API-DMAC7.html)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
WO2005063232A1 (en) * 2003-12-30 2005-07-14 Md Bioalpha Co., Ltd. Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity
US8029829B2 (en) 2005-02-03 2011-10-04 Taiyo Kagaku Co., Ltd. Preventive, relieving or therapeutic composition for diabetes mellitus and/or diabetic nephropathy
CN100341581C (zh) * 2005-07-29 2007-10-10 上海第二医科大学附属第九人民医院 一种丹酚酸b有效干预口腔癌动物模型的方法
US20070027209A1 (en) * 2005-08-01 2007-02-01 Lee Hyun C Prevention and treatment of atherosclerosis with lithospermate B
JP5169818B2 (ja) * 2006-03-07 2013-03-27 日本新薬株式会社 育毛剤
WO2008117901A1 (en) 2007-03-28 2008-10-02 Industry-Academic Cooperation Foundation, Yonsei University A method for isolation of high concentration of magnesium lithospermate b from salviae miltiorrhizae
US9345732B2 (en) 2009-11-19 2016-05-24 Laila Nutraceuticals Agents derived from Holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
CN102550916A (zh) * 2012-02-04 2012-07-11 王姗思 一种用于糖尿病肾病的食品
CN102614267A (zh) * 2012-04-24 2012-08-01 许风国 一种治疗糖尿病肾病的中药组合物及其制备方法
CN103830496A (zh) * 2014-02-28 2014-06-04 廊坊市思科农业技术有限公司 一种辅助降糖的组合物
CN104974119B (zh) * 2014-04-01 2018-10-19 中国科学院上海药物研究所 一种高纯度丹酚酸b镁及其制备方法
CN104547498A (zh) * 2014-12-31 2015-04-29 黎细乐 一种中药组合物的新用途
US20160361288A1 (en) * 2015-06-10 2016-12-15 Postech Academy-Industry Foundation Pharmaceutical compositions for preventing or treating diabetic nephropathy comprising the activity inhibitor of tenc1
CN105311413A (zh) * 2015-11-18 2016-02-10 暨南大学 治疗糖尿病肾病的含有艾叶的中药组合物及其制备方法
CN107551172A (zh) * 2017-10-26 2018-01-09 马雪英 一种治疗肾病综合症的药物及其制备方法
CN110215449A (zh) * 2019-05-13 2019-09-10 中国科学院长春应用化学研究所 紫草酸在抑制胰岛素淀粉样多肽聚集中的应用
CN112190646B (zh) * 2020-11-19 2021-12-28 首都医科大学附属北京中医医院 一种治疗糖尿病肾病的中药组合物及其制备方法
CN112569313B (zh) * 2020-12-28 2022-02-22 贵州三力制药股份有限公司 治疗肾病的中药组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01268682A (ja) * 1988-04-21 1989-10-26 Minofuaagen Seiyaku Honpo:Goushi 腎機能改善剤及びリソスペルミン酸塩の製造方法
US5358962A (en) * 1993-04-22 1994-10-25 Minophagen Pharmaceutical Company Antihypertensive method
JP3638967B2 (ja) * 1993-06-03 2005-04-13 日本ケミカルリサーチ株式会社 ネフローゼ症候群及び肝障害症状の寛解剤
JP3161882B2 (ja) * 1993-06-03 2001-04-25 日本ケミカルリサーチ株式会社 丹参由来多糖類、その製造法および用途
FI943242A7 (fi) * 1993-07-15 1995-01-16 Jcr Pharmaceutical Co Ltd Lääke munuais- ja maksatauteihin
US6149915A (en) * 1999-09-29 2000-11-21 Shiva Biomedical, Llc Treatment of diabetic nephropathy and microalbuminuria

Also Published As

Publication number Publication date
JP2003510286A (ja) 2003-03-18
US6267992B1 (en) 2001-07-31
WO2001022981A1 (en) 2001-04-05
US6149915A (en) 2000-11-21
AU4023501A (en) 2001-04-30
AU771275B2 (en) 2004-03-18
CN1387439A (zh) 2002-12-25
US20020025347A1 (en) 2002-02-28
EP1218020A1 (en) 2002-07-03

Similar Documents

Publication Publication Date Title
US6149915A (en) Treatment of diabetic nephropathy and microalbuminuria
Jin et al. Crocin attenuates isoprenaline-induced myocardial fibrosis by targeting TLR4/NF-κB signaling: connecting oxidative stress, inflammation, and apoptosis
Zou et al. Co-administration of hydrogen and metformin exerts cardioprotective effects by inhibiting pyroptosis and fibrosis in diabetic cardiomyopathy
Wang et al. Wheat germ-derived peptide ADWGGPLPH abolishes high glucose-induced oxidative stress via modulation of the PKCζ/AMPK/NOX4 pathway
Lu et al. Akebia Saponin D ameliorated kidney injury and exerted anti-inflammatory and anti-apoptotic effects in diabetic nephropathy by activation of NRF2/HO-1 and inhibition of NF-KB pathway
Oyedemi et al. In vitro anti-hyperglycemia properties of the aqueous stem bark extract from Strychnos henningsii (Gilg)
Duru et al. Anti-diabetic effect of isoflavone rich kudzu root extract in experimentally induced diabetic rats
Adeyemi et al. Hibiscus sabdariffa renews pancreatic β-cells in experimental type 1 diabetic model rats
Saravanan et al. Antidiabetic properties of S-allyl cysteine, a garlic component on streptozotocin-induced diabetes in rats
Zhou et al. Chrysin improves diabetic nephropathy by regulating the AMPK‐mediated lipid metabolism in HFD/STZ‐induced DN mice
CN113181150A (zh) Sr1078在制备治疗酒精性肝损伤药物方面的应用、药物组合物
Baek et al. Antihyperglycemic and Antilipidemic Effects of the Ethanol Extract Mixture of Ligularia fischeri and Momordica charantia in Type II Diabetes‐Mimicking Mice
Niu et al. Protective effects of Iridoid glycoside from Corni Fructus on type 2 diabetes with nonalcoholic fatty liver in mice
Zhang et al. Tangduqing granules attenuate insulin resistance and abnormal lipid metabolism through the coordinated regulation of PPARγ and DGAT2 in type 2 diabetic rats
Wang et al. Hypoglycemic effect and the mechanism of action of a polysaccharide from sweet corncob in a high-fat diet and streptozotocin-induced diabetic mice
CN102631358A (zh) 虎杖苷在制备糖尿病肾病治疗药物中的应用
CN119745925A (zh) 肝组织源性细胞外囊泡在治疗酒精性肝疾病中的应用
Lv et al. Network Pharmacology‐Based Approach to Explore the Total Flavonoids of Phellinus igniarius against Hyperuricemia via Regulating the Nrf2/HO‐1‐ROS‐ER Signaling Pathway
CN119424436A (zh) 化合物rociletinib通过抑制铁死亡在制备急性肝损伤的药物中的应用
Jiang et al. Effects of 95% ethanol extract of Aquilaria sinensis leaves on hyperglycemia in diabetic db/db mice
Wu et al. Clerodendranthus spicatus-Cordyceps cicadae regulates mitophagy and protects renal tubular epithelial cells from hyperuricemic nephropathy
Awad et al. Empagliflozin alleviates diabetic nephropathy in albino rats through its antioxidative and anti-inflammatory action
CN110314160B (zh) 小檗胺在制备预防和治疗糖尿病肾病药物中的应用
Oka et al. Effect of Hachimijiogan against Renal Dysfunction and Involvement of Hypoxia‐Inducible Factor‐1α in the Remnant Kidney Model
Alfarisi et al. Antidiabetic Effect of Acalypha hispida Extract and Nanoextract: Mechanism of Action on Pancreatic β‐Cell Function via Histone Acetylation

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued